Studies by Guo et al. and Liang et al. found that, when used in combination, trastuzumab sensitizes HER2+ breast cancer cells to radiation therapy in vitro, and that the upregulation of the PI3K/AKT pathway may be specifically involved in radioresistance in HER2+ breast cancer [5,7]. This evidence concerns the gene ERBB2 and breast carcinoma.